Cleerly

Cleerly is a cardiovascular-AI company that analyzes coronary CT angiography (CCTA) scans to quantify and characterize atherosclerotic plaque — the buildup in the arteries that drives most heart attacks. Its AI-guided quantitative CT (AI-QCT) approach measures the amount and type of plaque (for example, distinguishing higher-risk non-calcified plaque), aiming to move heart-disease assessment from indirect risk scores toward a direct, image-based picture of the disease in a given patient's arteries.

Cleerly is distinct from catalogued HeartFlow: where HeartFlow's flagship analysis models blood flow (FFR-CT) to assess whether a narrowing is functionally significant, Cleerly focuses on characterizing the plaque itself. The company reached an important reimbursement milestone with a Category I CPT code effective January 2026 and coverage from Medicare and major commercial payers, a signal that AI plaque analysis is moving into mainstream cardiology practice. As with all such tools, the clinical value depends on how results change management decisions, and adoption is still building; the reimbursement inflection is the key 2026 development to watch.